Data / Form D filings / GlucoTrack, Inc.
GlucoTrack, Inc.: Form D filings
GlucoTrack, Inc., a biotechnology company in Rutherford, NJ, filed 10 Form D notices with the SEC between 2010 and 2024. The latest, on May 8, 2024, reports $500,000 sold of a $500,000 offering to 9 investors.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 301 ROUTE 17 NORTH SUITE 800, Rutherford, NJ, 07070
- Phone
- (201) 842-7715
- Industry
- Biotechnology
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(b)
- SEC identifier (CIK)
- 1506983
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| May 8, 2024 | New notice | $500,000 | $500,000 | 9 | Apr 22, 2024 | sec.gov | |
| Feb 28, 2020 | New notice | $15,000,000 | $15,000,000 | 1 | Feb 14, 2020 | sec.gov | |
| Dec 11, 2017 | New notice | $10,000,000 | $425,000 | $9,575,000 | 6 | Dec 1, 2017 | sec.gov |
| Jun 28, 2017 | Amendment | $12,000,000 | $11,003,800 | $996,200 | 96 | Apr 8, 2016 | sec.gov |
| Jan 20, 2017 | Amendment | $12,000,000 | $6,232,800 | $5,767,200 | 78 | Apr 8, 2016 | sec.gov |
| Apr 18, 2016 | New notice | $12,000,000 | $1,133,000 | $10,867,000 | 17 | Apr 8, 2016 | sec.gov |
| Sep 12, 2014 | New notice | $8,500,000 | $3,036,000 | $5,464,000 | 31 | Aug 29, 2014 | sec.gov |
| Mar 28, 2013 | Amendment | $7,455,399 | $7,455,399 | 89 | Nov 19, 2012 | sec.gov | |
| Dec 3, 2012 | New notice | $5,500,000 | $1,155,399 | $4,344,601 | 27 | Nov 19, 2012 | sec.gov |
| Dec 27, 2010 | New notice | $12,500,000 | $3,566,047 | $8,933,953 | 57 | Dec 15, 2010 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Paul Goode | Executive Officer | |
| Shimon Rapps | Director | |
| Andrew Sycoff | Director | |
| Erin Carter | Director | |
| Luis Malave | Director | |
| Allen Danzig | Director | |
| James Cardwell | Executive Officer | |
| Robert Fischell | Director |
Other biotechnology companies in New Jersey that filed recently
- Ensho Therapeutics, Inc. $7.3 million · Oct 15, 2026
- Xenon Ophthalmics Inc $3.3 million · Oct 6, 2026
- LISATA THERAPEUTICS, INC. $351.9 million · Oct 2, 2026
- Bullseye Biodevices, Inc. $1.3 million · Aug 10, 2026
- Hepion Pharmaceuticals, Inc. $3.1 million · Aug 5, 2026
Every Form D from the week of May 6, 2024 · All recent filings in New Jersey · All recent Biotechnology filings
Read from SEC EDGAR. Amount sold is what GlucoTrack, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.